A Message From Our CEO

Nanodose Therapeutics is focused on using biological molecules in settings where less can be more.  Nanodose scientists look at biological systems through a lens that focuses on returning them to normal health – sometimes called “homeostasis” – by restoring normal cellular signaling rather than the more common agonist/antagonist methods. 

​

Our scientific legacy will be built on how effective we are in advancing innovative approaches and technology to treat chronic and rare conditions. We are poised to expand our understanding and approach to other conditions that also are affected by gene signaling. Our nanodosing approach can bring new, innovative medicines to the marketplace that have the potential to transform lives and bring new hope in ways never thought possible. While we have four promising platforms, we are focused on getting our lead asset (NT-101) for the treatment of chronic Traumatic Brain Injury into phase I trials in 2026 and into a Phase II proof-of-concept trial in 2027.

 

I would like to offer my sincere thanks to all who have freely given their trust and confidence to our mission. The hard work and dedication by our employees and our collaborators are what make our dreams possible. We look forward to delivering on our expectations in 2024 and beyond. And on behalf of the entire company and our board of directors, I would like to thank you and invite you to take a look around our website. We look forward to working with you, partnering with you, or serving you in the future.

​

​

Richard Sandberg

Chief Executive Officer & Co-Chairman of the Board